A recent development in a legal battle involving OSRX Inc., an eye drop maker, has emerged as the Fourth Circuit panel opted to partially revive a lawsuit concerning trade secret theft. The lawsuit centers on a former sales executive accused of defecting to competitor ImprimisRx, allegedly taking OSRX’s confidential information with him. Importantly, while the panel has affirmed the lower court’s decision to move the claims against the ex-executive to arbitration, it has reignited allegations specifically targeting ImprimisRx.
This case underscores the ongoing challenges corporations face in protecting their intellectual property and trade secrets, particularly when key personnel transition to rival firms. For more details about the specifics of this case and its implications, you can access the full coverage provided by Law360 here.